Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5'-O-[(L-methionyl)-sulphamoyl]adenosine is a synthetic small molecule that acts as an analogue of aminoacyl-adenosine monophosphate. It is primarily studied as an experimental inhibitor of aminoacyl-tRNA synthetases, particularly methionine--tRNA ligase, which are enzymes essential for protein synthesis. The compound features a methionyl group linked to adenosine via a stable sulfamoyl bond, enhancing its binding affinity and inhibitory properties compared to natural substrates. By mimicking the natural substrate's interactions within the catalytic pocket of aminoacyl-tRNA synthetases, it competitively inhibits these enzymes and disrupts normal protein synthesis pathways. This mechanism makes it valuable in biochemical research and as a potential lead compound for developing new antibacterial agents targeting translational control[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5'-O-[(L-methionyl)-sulphamoyl]adenosine.